enGene Therapeutics (ENGN) Gains from Investment Securities (2023)
enGene Therapeutics (ENGN) posted quarterly Gains from Investment Securities of -$6.9 million for Q4 2023, down 24.14% quarter-over-quarter from -$5.5 million in Q3 2023.
enGene Therapeutics (ENGN) Gains from Investment Securities (2023) Analysis & Trends
enGene Therapeutics (ENGN) has reported Gains from Investment Securities for 1 consecutive years, with -$6.9 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Gains from Investment Securities changed N/A year-over-year to -$6.9 million; the TTM figure through Oct 2023 stood at -$10.8 million (changed N/A YoY), while the FY2023 annual figure was -$10.8 million, down 426.19% from the prior year.
- Gains from Investment Securities eased to -$6.9 million in Q4 2023 per ENGN's latest filing, from -$5.5 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.2 million in Q1 2023 and bottomed at -$6.9 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2023 | -6.85 Mn |
| Oct 31, 2023 | -6.85 Mn |
| Jul 31, 2023 | -5.52 Mn |
| Jul 31, 2023 | -5.52 Mn |
| Apr 30, 2023 | 341,000.00 |
| Apr 30, 2023 | 341,000.00 |
| Jan 31, 2023 | 1.19 Mn |
| Jan 31, 2023 | 1.19 Mn |